Gland Pharma Q1 Results: Net Profit Surges 50% YoY to Rs 215.4 Cr; Revenue Rises 7.4%, EBITDA Jumps 39%

Gland Pharma has reported a strong set of numbers for the first quarter of the financial year 2025-26 (Q1FY26), posting a sharp rise in profitability on the back of healthy revenue growth and significant margin expansion.

Gland Pharma Q1 Results: Net Profit Jumped 50% YoY

The Hyderabad-based injectable-focused pharmaceutical company saw its consolidated net profit jump by an impressive 49.9% year-on-year (YoY) to Rs 215.4 crore, compared to Rs 143.7 crore in the same period last year. This substantial growth in net profit reflects both operational efficiency and a favorable product mix in key markets.

Revenue from operations also showed resilience, growing by 7.4% YoY to Rs 1,505.6 crore in Q1FY26 as against Rs 1,401.7 crore in Q1FY25. The growth, though modest, was driven by improved demand in regulated markets, better realisation in existing contracts and increased contribution from contract development and manufacturing operations (CDMO).

The company's performance comes at a time when the broader pharma sector has been navigating pricing pressures in the US and regulatory headwinds.

Gland Pharma Q1 EBITDA

One of the major highlights of the quarter was Gland Pharma's robust improvement in operating profitability. The company's EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) rose 39% YoY to Rs 367.6 crore, up from Rs 264.5 crore in the corresponding quarter of the previous year.

As a result, EBITDA margins expanded significantly to 24.4%, compared to 19% in Q1FY25.

Focus on R&D and Product Launches in Q1FY26

Gland Pharma continued to strengthen its innovation pipeline in the first quarter of FY26, with research and development (R&D) expenses reaching Rs 46 crore, accounting for 4.4% of the company's total revenue during the period.

As part of its Q1 efforts, the company successfully launched 12 new molecules, including key injectable formulations such as colistimethate, epinephrine, vancomycin (in three new dosage strengths), liraglutide, and acetaminophen IV bags. These product additions are expected to support the company's growth momentum across critical care, diabetes management and hospital-based therapies in global markets.